Moran Wealth Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.36M Buy
62,009
+3,794
+7% +$171K 0.09% 255
2026
Q2
$2.45M Buy
58,215
+9,011
+18% +$287K 0.07% 296
2026
Q1
$1.3M Buy
49,204
+21,811
+80% +$639K 0.04% 341
2025
Q4
$794K Buy
27,393
+4,747
+21% +$142K 0.02% 370
2025
Q3
$629K Buy
22,646
+9,855
+77% +$249K 0.02% 382
2025
Q2
$311K Buy
+12,791
New +$280K 0.01% 451

Other funds holding ARKG

Moran Wealth Management's ARKG Position: Q3 2026 in Review

Moran Wealth Management increased its ARK Genomic Revolution ETF (ARKG) stake by 6.5% in Q3 2026, buying an estimated $171K and bringing the position to 62,009 shares worth $3.36M. The position accounts for 0.09% of the portfolio, ranked #255.

Moran Wealth Management first reported a position in ARKG in Q2 2025 and has held it in 6 quarters since. 211 funds tracked by Wall St. Rank hold ARKG as of Q3 2026.

  • Moran Wealth Management held 62,009 shares of ARK Genomic Revolution ETF worth $3.36M as of Q3 2026.
  • Moran Wealth Management bought 3,794 ARK Genomic Revolution ETF shares in Q3 2026, an estimated $171K.
  • ARK Genomic Revolution ETF made up 0.09% of Moran Wealth Management's portfolio in Q3 2026, its #255 holding.
  • Moran Wealth Management first reported a position in ARK Genomic Revolution ETF in Q2 2025 and has held it in 6 quarters since.
  • 211 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2026.

Based on Moran Wealth Management's 13F filing for Q3 2026, filed 22 Oct 2026.